Needham, Absci
"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Absci Corp (ABSI) stock saw a modest uptick, ending the day at $2.9 which represents a slight increase of $0.10 or 3.57% from the prior close of $2.8. The stock opened at $2.86 and touched a low of $2 ...
Absci management is scheduled to participate in a fireside chat on Wednesday, February 5 th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...
Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback